Rituximab induces distinct intraorbital and intrathyroidal effects in one patient satisfactorily treated for graves' ophthalmopathy

Clinical Reviews in Allergy and Immunology

Volumn 34, Issue 1, 2008, Pages 118-123

  Bonara, P ^a   Vannucchi, G ^b   Campi, I ^b   Rossi, S ^c   Cantoni, F ^a   Frugoni, C ^a   Sbrozzi, F ^a   Guastella, C ^a   Avignone, S ^a   Beck Peccoz, P ^b   Salvi, M ^b  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c Azienda Ospedaliera San Paolo   (Italy)

Author keywords

Graves' disease; Ophthalmopathy; Rituximab

Indexed keywords

INSULIN; LEVOTHYROXINE; LUBRICATING AGENT; METHYLPREDNISOLONE; PROPRANOLOL; RADIOACTIVE IODINE; RITUXIMAB; THIAMAZOLE; THYROID ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; B LYMPHOCYTE; CASE REPORT; DECOMPRESSION SURGERY; DIPLOPIA; DRUG MECHANISM; DRUG WITHDRAWAL; ENDOCRINE OPHTHALMOPATHY; EPIPHORA; EXOPHTHALMOS; EYE EXAMINATION; EYE TOXICITY; EYELID DISEASE; FEMALE; FOLLOW UP; GRAVES DISEASE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTHYROIDISM; IMMUNOHISTOCHEMISTRY; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE DEPLETION; NOSE OCCLUSION; OPHTHALMOLOGY; ORBIT; PATIENT SATISFACTION; THYROID FUNCTION; THYROIDECTOMY;

ANTIBODIES, MONOCLONAL; B-LYMPHOCYTES; FEMALE; GRAVES OPHTHALMOPATHY; HUMANS; IMMUNOLOGIC FACTORS; MIDDLE AGED; ORBIT; THYROID GLAND; THYROIDECTOMY; TREATMENT OUTCOME;

EID: 49349084990     PISSN: 10800549     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12016-007-8024-3     Document Type: Article

References (28)

1. M Zakarija JM McKenzie 1987 The spectrum and significance of autoantibodies reacting with the thyrotropin receptor Endocrinol Metab Clin N Am 16 343 363
2. B Rees Smith SM McLachlan J Furmaniak 1988 Autoantibodies to the thyrotropin receptor Endocr Rev 8 106 121
3. C Segundo C Rodriguez A Garcia-Poley M Aguilar I Gavilan C Bellas JA Brieva 2001 Thyroid-infiltrating B lymphocytes in Graves' disease are related to marginal zone and memory B cell compartments Thyroid 11 525 530
4. V Michelangeli C Poon J Taft H Newnham D Topliss P Colman 1998 The prognostic value of thyrotropin receptor antibody measurement in the early stages of treatment of Graves' disease with antithyroid drugs Thyroid 8 119 124
5. RS Bahn 2003 Clinical review 157: pathophysiology of Graves' ophthalmopathy: the cycle of disease J Clin Endocrinol Metab 88 1939 1946
6. RW Valyasevi DA Harteneck CM Dutton RS Bahn 2002 Stimulation of adipogenesis, peroxisome proliferator-activated receptor-gamma (PPARgamma), and thyrotropin receptor by PPARgamma agonist in human orbital preadipocyte fibroblasts J Clin Endocrinol Metab 87 2352 2358
7. HJ Cao HS Wang Y Zhang HY Lin RP Phipps TJ Smith 1998 Activation of human orbital fibroblasts through CD40 engagement results in a dramatic induction of hyaluronan synthesis and prostaglandin endoperoxide H synthase-2 expression: insights into potential pathogenic mechanisms of thyroid-associated ophthalmopathy J Biol Chem 273 29615 29625
8. T Mikozami M Salvi JR Wall 2004 Eye muscle antibodies in Graves' ophthalmopathy: pathogenic or secondary epiphenomenon? J Endocrinol Investig 27 221
9. MN Gerding JW van der Meer M Broenink O Bakker WM Wiersinga MF Prummel 2000 Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy Clin Endocrinol 52 267 271
10. A De Bellis A Bizzarro M Conte C Solimeno S Perrino D Sansone M Guaglione JR Wall A Bellastella 2003 Relationship between longitudinal behaviour of some markers of eye autoimmunity and changes in ocular findings in patients with Graves' ophthalmopathy receiving corticosteroid therapy Clin Endocrinol 59 388 395
11. S Kubota H Ohye E Nishihara T Kudo M Ito S Fukata N Amino K Kuma A Miyauchi 2005 Effect of high dose methylprednisolone pulse therapy followed by oral prednisolone administration on the production of anti-TSH receptor antibodies and clinical outcome in Graves' disease Endocr J 52 735 741
12. AK Eckstein M Plicht L Hildegard M Neuhauser K Mann S Lederbogen C Heckmann J Esser NG Morgenthaler 2006 TSH-receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease J Clin Endocrinol Metab 91 3464 3470
13. GC Tsokos 2004 B cells be gone-B-cell depletion in the treatment of rheumatoid arthritis N Engl J Med 350 2546 2548
14. MD Pescovitz 2006 Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action American Journal of Transplantation 6 859 866
15. HC Hasselbalch 2003 B-cell depletion with rituximab-a targeted therapy for Graves' disease and autoimmune thyroiditis Immunol Lett 88 85 86
16. M Salvi G Vannucchi I Campi N Currò D Dazzi S Simonetta P Bonara S Rossi C Sina C Guastella R Ratiglia P Beck-Peccoz 2007 Treatment of Graves' disease and associated ophthalmopathy with the monoclonal antibody rituximab: an open study Eur J Endocrinol 156 33 40
17. SC Werner 1969 Classification of the eye changes of Graves' disease J Clin Endocrinol Metab 29 982 984
18. MP Mourits MF Prummel WM Wiersinga L Koorneef 1997 Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy Clin Endocrinol 47 9 14
19. D El Fassi CH Nielsen HC Hasselbalch L Hegedus 2005 Successful B lymphocyte depletion in a patient with recurrent Graves' disease and severe ophthalmopathy Thyroid 15 Suppl 1 S28
20. Male D, Cooke A, Owen M, Trowsdale J, Champion B (1996) Antigen receptor molecules. In Male D, Cooke A, Owen M, Trowsdale J, Champion B (eds) Advanced immunology. Mosby, London, pp 2.1-2.2
21. JH Anolik D Campbell RE Felgar J Rosenblatt F Young I Sanz RJ Looney 2002 B lymphocyte depletion in the treatment of systemic lupus erythematosus Arthritis Rheum Suppl 9 S717
22. JC Edwards L Szczepanski J Szechinski A Filipowicz-Sosnowska P Emery DR Close RM Stevens T Shaw 2004 Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis N Engl J Med 350 2572 2581
23. R Stasi A Pagano E Stipa S Amadori 2001 Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura Blood 98 952 957
24. MJ Leandro JC Edwards G Cambridge 2002 Clinical outcome in 22 patients with rheumatoid arthritis treated for B lymphocyte depletion Ann Rheum Dis 61 883 888
25. MP Armengol M Juan A Lucas-Martin MT Fernandez-Figueras D Jaraquemada T Gallart R Pujol-Borrell 2001 Thyroid autoimmune disease: demonstration of thyroid antigen-specific B-cells and recombination-activating gene expression in chemokine-containing active intrathyroidal germinal centers Am J Pathol 159 861 873
26. C Gorman M Leandro D Isenberg 2003 B-cell depletion in autoimmune disease Arthritis Research and Therapy 5 Suppl 4 S17 S21
27. S Takemura PA Klimiuk A Braun JJ Goronzy CM Weyand 2001 T cell activation in rheumatoid synovium is B-cell dependent J Immunol 167 4710 4718
28. J Pritchard S Tsui N Horst WW Cruikshank TJ Smith 2004 Synovial fibroblasts from patients with rheumatoid arthritis, like fibroblasts from Graves'disease, express high levels of IL-16 when treated with Igs against insulin-like growth factor-1 receptor J Immunol 173 3564 3569